STOCK TITAN

ParkerVision permits resale of up to 18M shares

ParkerVision receives no proceeds from selling-stockholder resales; cash exercise of the consulting warrant could generate up to $180,000 in gross proceeds.

(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
424B3

Rhea-AI Filing Summary

ParkerVision, Inc. (PRKR) states that its prospectus permits selling stockholders to resell up to 18,014,164 shares of common stock. The shares include stock issuable upon conversion of two note tranches, 625,000 shares issued for consulting services, and 1,800,000 shares issuable under a consulting warrant with a $0.10 exercise price.

ParkerVision receives no proceeds from selling-stockholder resales; it could receive up to $180,000 in gross proceeds if the warrant is exercised for cash, for general working capital and corporate purposes. At its September 25, 2026 annual meeting, shareholders elected two directors and ratified Frazier & Deeter, LLC as the independent registered public accounting firm for the year ending December 31, 2026.

Shares permitted for resale up to 18,014,164 shares ParkerVision common stock
Tranche 1 Notes conversion shares up to 5,457,583 shares Shares issuable upon conversion of Tranche 1 Notes
Tranche 2 Notes conversion shares up to 10,131,581 shares Shares issuable upon conversion of Tranche 2 Notes
Consulting-service shares up to 625,000 shares Issued as payment for services under the Fisher Consulting Agreement
Park Consulting Warrant shares up to 1,800,000 shares Shares issuable upon exercise
Park Consulting Warrant exercise price $0.10 per share Subject to adjustment
Potential gross proceeds from warrant exercise up to $180,000 If the Park Consulting Warrant is exercised for cash
Tranche 1 Notes financial
"fixed conversion price of $0.10 per share (the “Tranche 1 Notes”)"
Tranche 2 Notes financial
"fixed conversion price of $0.08 per share (the “Tranche 2 Notes”)"
Park Consulting Warrant financial
"a five-year warrant with an exercise price of $0.10 per share"
Broker Non-Vote financial
"Votes For | Votes Against | Votes Withheld | Broker Non-Vote"
A broker non-vote happens when a brokerage firm holds shares in street name for a client but does not cast a ballot on a particular shareholder item because the broker lacks discretionary authority to vote that matter. Think of it like a person who owns a ticket but the ticket-holder refuses to vote on some issues; the share counts for ownership but not for that vote, which can affect whether proposals reach the required number of votes or a quorum.
Offering Type secondary
Securities Offered Common Stock
Offering Amount 18,014,164 shares
Use of Proceeds ParkerVision expects to use proceeds from any cash exercise of the Park Consulting Warrant for general working capital and corporate purposes.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many PRKR shares may selling stockholders resell?

The prospectus permits selling stockholders to resell up to 18,014,164 shares of ParkerVision common stock. The shares include stock issuable upon conversion of the Tranche 1 and Tranche 2 Notes, shares issued for consulting services, and shares issuable under the Park Consulting Warrant.

Does ParkerVision receive proceeds from PRKR share resales?

ParkerVision receives no proceeds from sales by selling stockholders. If the Park Consulting Warrant is exercised for cash, ParkerVision could receive up to $180,000 in gross proceeds, which it expects to use for general working capital and corporate purposes.

Which directors were elected at PRKR's 2026 annual meeting?

Shareholders elected Jeffrey L. Parker as a Class I director for a term expiring at the 2029 annual meeting and Anthony B. Bowers as a Class II director for the remaining term expiring at the 2027 annual meeting. Jeffrey L. Parker received 21,862,556 votes for, 0 against, 837,457 withheld, and 71,479,395 broker non-votes. Anthony B. Bowers received 22,063,764 votes for, 0 against, 636,249 withheld, and 71,479,395 broker non-votes.

Did PRKR shareholders ratify the accounting firm for 2026?

Shareholders ratified Frazier & Deeter, LLC as ParkerVision's independent registered public accounting firm for the year ending December 31, 2026. The selection received 93,703,944 votes for, 51,229 against, and 424,235 abstentions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

Filed pursuant to Rule 424(b)(3)

Registration No. 333-233390

 

PROSPECTUS SUPPLEMENT No. 83

(to Prospectus dated September 11, 2019)

 

PARKERVISION, INC.

18,014,164 Shares of Common Stock

 

This Prospectus Supplement relates to the prospectus dated September 11, 2019, as amended and supplemented from time to time (the “Prospectus”) which permits the resale by the selling stockholders listed in the Prospectus of up to 18,014,164 shares of our common stock, par value $0.01 per share (“Common Stock”) consisting of (i) up to 5,457,583 shares of Common Stock issuable upon conversion of, and for the payment of interest from time to time at our option, for convertible promissory notes dated June 7, 2019 through July 15, 2019 which have a fixed conversion price of $0.10 per share (the “Tranche 1 Notes”), (ii) up to 10,131,581 shares of Common Stock issuable upon conversion of, and for the payment of interest from time to time at our option, for convertible promissory notes dated July 18, 2019 which have a fixed conversion price of $0.08 per share (the “Tranche 2 Notes”), (iii) up to 625,000 shares of Common Stock issued as payment for services in conjunction with a consulting agreement dated June 7, 2019 (the “Fisher Consulting Agreement”) and (iv) up to 1,800,000 shares of Common Stock issuable upon exercise of a five-year warrant with an exercise price of $0.10 per share, subject to adjustment and issued as payment for services in conjunction with a consulting agreement dated July 22, 2019 (the “Park Consulting Warrant”).

 

We will not receive proceeds from the sale of the shares of Common Stock by the selling stockholders. To the extent the Park Consulting Warrant is exercised for cash, we will receive up to an aggregate of $180,000 in gross proceeds. We expect to use proceeds received from the exercise of the Park Consulting Warrant, if any, for general working capital and corporate purposes.

 

This Prospectus Supplement is being filed to update and supplement the information previously included in the Prospectus with the information contained in our Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on September 28, 2026.  Accordingly, we have attached the 8-K to this prospectus supplement.  You should read this prospectus supplement together with the prospectus, which is to be delivered with this prospectus supplement.

 

Any statement contained in the Prospectus shall be deemed to be modified or superseded to the extent that information in this Prospectus Supplement modifies or supersedes such statement.  Any statement that is modified or superseded shall not be deemed to constitute a part of the Prospectus except as modified or superseded by this Prospectus Supplement.

 

This Prospectus Supplement should be read in conjunction with, and may not be delivered or utilized without, the Prospectus.

 

Our Common Stock is listed on the OTCQB Venture Capital Market under the ticker symbol “PRKR.” 

 

Investing in our securities involves a high degree of risk. See “Risk Factors” beginning on page 5 of this prospectus for a discussion of information that should be considered in connection with an investment in our securities.

 

Neither the SEC nor any such authority has approved or disapproved these securities or determined whether this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

 

The date of this Prospectus Supplement is September 28, 2026.

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

______________

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): September 25, 2026

 

PARKERVISION, INC.

(Exact Name of Registrant as Specified in Charter)

     

Florida

000-22904

59-2971472

(State or Other Jurisdiction of Incorporation)

(Commission File Number)

(IRS Employer Identification No.)

 

   

4446-1A Hendricks Avenue Suite 354, Jacksonville, Florida

32207

(Address of Principal Executive Offices)

(Zip Code)

 

(904) 732-6100

(Registrant’s Telephone Number, Including Area Code)

 

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

   

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

   

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

   

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e 4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class

Trading Symbol

Name of Each Exchange on Which Registered

None

 

 

 

 

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter.

 

Emerging growth company   ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ☐

 

 

 

 

Item 5.07 - Submission of Matters to a Vote of Security Holders.

 

The Company held its Annual Meeting of Shareholders (the “Annual Meeting”) on September 25, 2026.  The record date for shareholders entitled to notice of, and to vote at, the Annual Meeting was July 29, 2026.  At the close of business on that date, the Company had 148,226,874 shares of common stock issued and outstanding and entitled to be voted at the Annual Meeting.  Two proposals were submitted to the Company’s shareholders at the Annual Meeting.  The proposals are described in more detail in the Company’s definitive proxy statement filed with the U.S. Securities and Exchange Commission on August 11, 2026.  The final voting results were as follows:

 

Proposal 1

 

The Company’s shareholders elected the following Class I Director to serve for a term expiring at the 2029 annual meeting.  The voting results are set forth below. 

 

 

Votes For

Votes Against

Votes Withheld

Broker Non-Vote

Jeffrey L. Parker

21,862,556

0

837,457

71,479,395

 

 

The Company's shareholders also elected the following Class II Director to serve for the remaining Class II term expiring at the 2027 annual meeting.

 

 

Votes For

Votes Against

Votes Withheld

Broker Non-Vote

Anthony B. Bowers

22,063,764

0

636,249

71,479,395

 

Proposal 2

 

The Company’s shareholders ratified the selection of Frazier & Deeter, LLC as the Company’s independent registered public accounting firm for the year ending December 31, 2026.  The voting results are set forth below.

 

Votes For

Votes Against

Votes Abstained

Broker Non-Vote

93,703,944

51,229

424,235

N/A

 

 

 Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits:

 

Exhibit

Description

104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

     

Dated: September 28, 2026

   
   

PARKERVISION, INC.

     
   

By /s/ Cynthia French

   

Cynthia French

   

Chief Financial Officer

 

 

Keep reading